Poor outcome with anti-programmed death-ligand 1 (PD-L1) antibody due to poor pharmacokinetic properties in PD-1/PD-L1 blockade-sensitive mouse models
======================================================================================================================================================

* Taiki Kurino
* Reiko Matsuda
* Ayu Terui
* Hiroyuki Suzuki
* Tomomi Kokubo
* Tomoya Uehara
* Yasushi Arano
* Akihiro Hisaka
* Hiroto Hatakeyama